Synthomer

SYNT · Main Market · Chemicals · mcap £189m · 113.0p 2 open situations →

Beta Briefing, track record and signals & risks are not ready for Synthomer yet.

We follow 960 UK small caps and every one of their announcements – often hundreds per company. 101 companies are already wired into a briefing: browse them.

Timeline · every situation

dots = announcements

2026 Broadened divestment programme Cost savings programme Debt refinancing and possible capital raise 1 director buying 4 directors buying

Open · 2

Disposal of a part (break-up)

Broadened divestment programme

Acrylate Monomers sale completed; three processes continue

Divestment programme broadened Oct 2025. Acrylate Monomers sale announced 19 June 2026 and shown as discontinued in the 4 Aug 2026 interims (H1 EBITDA £(0.4)m). Completed on 30 Sep 2026 in line with the announced terms. Price and buyer are not stated here. Three further processes are underway, and the Dec 2026 leverage target excludes further divestments.

Price: Not stated in this announcement 30 Sep 2026 ↗
Use of money: Simplify manufacturing and reduce debt 4 Aug 2026 ↗
Other projects: Three further divestment processes underway (per 4 Aug 2026 interims) 30 Sep 2026 ↗
Next milestone: Interim results on 4 August 2026 22 Jun 2026 ↗
Buyer: Not stated in this announcement 30 Sep 2026 ↗
Leverage target: Dec 2026 covenant net debt:EBITDA 4.0-4.35x, excluding further divestments 4 Aug 2026 ↗

Next: Update on three further divestment processes

30 Sep 2026 Acrylate Monomers sale completed; three processes continue
4 Aug 2026 Acrylate Monomers announced; three more underway
22 Jun 2026 First deal (Acrylate Monomers) announced; others continuing
30 Apr 2026 Four projects underway; no deal announced

Open the full view – chart and every step →

Turnaround plan with targets

Cost savings programme

c.£13m delivered in H1 2026

Self-help cost programme since Oct 2025. £30m of benefit was delivered in 2025, with a further c.£20-25m gross expected in 2026 after about 250 role removals. The H1 2026 interims report c.£13m of year-on-year run-rate benefits, so the programme is on track. Savings help support the £8m of underlying H1 EBITDA progress.

2025 delivered: c.£30m self-help benefits 4 Aug 2026 ↗
2026 target: c.£20-25m incremental gross benefits 4 Aug 2026 ↗
Headcount: Around 250 roles removed in H2 2025 4 Aug 2026 ↗
Margin effect: Gross margin +200bps; EBITDA margin +40bps to 7.8%
H1 2026 delivered: c.£13m year-on-year run-rate benefits 4 Aug 2026 ↗

Next: H2 delivery of the c.£20-25m 2026 savings target

4 Aug 2026 c.£13m delivered in H1 2026
30 Apr 2026 £30m delivered in 2025; more to come in 2026
19 Mar 2026 Self-help actions driving 2026 progress
29 Jan 2026 Expanded programmes delivering; 2026 full-year benefit

Open the full view – chart and every step →

Closed · 3

Balance-sheet stress / refinancingDebt refinancing and possible capital raise Refinanced to 2029; covenants reset · 11 Feb 2026 – 30 Apr 2026 Insider conviction1 director buying £31k in 1 buy · 12 Nov 2025 – 10 Feb 2026 +114% Insider conviction4 directors buying £87k in 4 buys · 4 Jul 2025 – 9 Nov 2025 −35%

Company filings. Not investment advice.